Pomolic acid may overcome multidrug resistance mediated by overexpression of anti-apoptotic Bcl-2 proteins

Cancer Letters

Volumn 245, Issue 1-2, 2007, Pages 315-320

  Fernandes, Janaina ^a   Weinlich, Ricardo ^b   Castilho, Rachel Oliveira ^c   Amarante Mendes, Gustavo Pessini ^b   Gattass, Cerli Rocha ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSIDADE CATÓLICA DOM BOSCO   (Brazil)

Author keywords

Anti apoptotic proteins; Apoptosis; Bcl 2 and Bcl xL; Leukemia; MDR; Pomolic acid

Indexed keywords

CASPASE 3; CASPASE 9; POMOLIC ACID; PROTEIN BCL 2; PROTEIN BCL XL; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL STRAIN HL 60; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CASPASE 9; DNA FRAGMENTATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIAL MEMBRANES; OLEANOLIC ACID; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 33845897954     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.01.009     Document Type: Article

References (39)

1. Lauria F., Raspadori D., Rondelli D., Ventura M.A., Fiacchini M., Visani G., et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 11 (1997) 2075-2078
2. Reed J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17 (1999) 2941-2953
3. Williams J., Lucas P., Griffith K.A., Choi M., Fogoros S., Hu Y.Y., et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol. Oncol. 96 (2005) 287-295
4. Larsen A.K., Escargueil A.E., and Skladonowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther. 85 (2000) 217-229
5. Haimeur A., Conseil G., Deeley R.G., and Cole S.P. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab. 5 (2004) 21-23
6. Duvvuri M., and Krise J.P. Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front. Biosci. 10 (2005) 1499-1509
7. Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84 (1994) 3148-3157
8. Pepper C., Hoy T., and Bentley D.P. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br. J. Cancer 76 (1997) 935-938
9. Noutomi T., Chiba H., Itoh M., Toyota H., and Mixuguichi J. Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncol. 38 (2002) 41-48
10. Shi X., Liu S., Kleeff J., Friess H., and Buchler M.W. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62 (2002) 354-362
11. Costantini P., Jacotot R., Decaudin D., and Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J. Natl Cancer Inst. 92 (2000) 1042-1053
12. Debatin K.-M., Poncet D., and Kroemer G. Chemotherapy, targeting the mitochondrial cell death pathway. Oncogene 21 (2002) 8786-8803
13. Green D.R., and Kroemer G. The central executioners of apoptosis: caspases or mitochondria?. Trends Cell Biol. 89 (1998) 267-271
14. Marzo I., Brenner C., Zamzami N., Susin S.A., Beutner G., Brdiczka D., et al. The permeability transition pore complex: a target for apoptosis regulation by caspases and Bcl-2-related proteins. J. Exp. Med. 187 (1998) 1261-1271
15. Shimizu S., Konishi A., Kodoma T., and Tsujimoto Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc. Natl Acad. Sci. 97 (2000) 3100-3105
16. Burlacu A. Regulation of apoptosis by Bcl-2 family proteins. J. Cell. Mol. Med. 7 (2003) 249-257
17. Cheng E.H.-Y.A., Wei M.C., Weiler S., Flavell R.A., Mak T.W., Lindsten T., et al. BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8 (2001) 705-711
18. Shangary S., and Johnson D.E. Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-xL and Bax oligomerization, induction of cytochrome c release, and activation of cell death. Biochemistry 41 (2002) 9485-9495
19. Del G., Venditti A., Del Principe M.I., Maurillo L., Buccisano F., Tamburini A., et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101 (2003) 2125-2131
20. Desoise B. Anticancer drug resistance and inhibition of apoptosis. Anticancer Res. 14 (1994) 2291-2294
21. Cho H.J., Kim J.K., Kim K.D., Yoon H.K., Cho M.Y., Park Y.P., et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett. July (2005) (Epub ahea of print)
22. Campos L., Rouault J.P., Sabido O., Oriol P., Roubi N., Vasselon C., et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81 (1993) 3091-3096
23. Prokop A., Wieder T., Sturm I., Essmann F., Seeger K., Wuchter C., et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 14 (2000) 1606-1613
24. Rosser C.J., Reyes A.O., Vakar-Lopez F., Levy L.B., Kuban D.A., Hoover D.C., et al. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 56 (2003) 1-6
25. Olopade O.I., Adeyanju M.O., Safa A.R., Safos F., Mick R., Thompson C.B., et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J. Sci. Am. 3 (1997) 230-237
26. Quinn D.I., Henshall M.S.M., and Sutherland R.L. Molecular markers of prostate cancer outcome. Eur. J. Cancer 41 (2005) 858-887
27. Espana L., Fernandez Y., Rubio N., Torregrosa A., Blanco J., and Sierra A. Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis. Breast Cancer Res. Treat. 87 (2004) 33-44
28. Fernandes J., Castilho R.O., Costa M.R., Wagner-Souza K., Kaplan M.A.C., and Gattass C.R. Pentacyclic triterpenes from Chrysobalanaceae species: cytotoxicity on multidrug resistant and sensitive leukemia cell lines. Cancer Lett. 190 (2003) 165-169
29. Rumjanek V.M., Trindade G.S., Wagner-Souza K., Meletti-de-Oliveira M.C., Marques-Santos L.F., Maia R.C., et al. Multidrug resistance in tumor cells: characterization of the multidrug resistant cell line K562-Lucena 1. An. Acad. Bras. Cienc. 73 (2001) 57-69
30. Fernandes J., Weinlich R., Castilho R.O., Kaplan M.A.C., Amarante-Mendes G.P., and Gattass C.R. Pomolic acid triggers mitochondria-dependent apoptotic cell death in leukemia cell line. Cancer Lett. 219 (2005) 49-55
31. Brumatti G., Weinlich R., Chehab C.F., Yon M., and Amarante-Mendes G.P. Comparison of the anti-apoptotic effects of crab, Bcl-2 and Bcl-xL following diverse apoptogenic stimuli. Fed. Eur. Biochem. Soc. Lett. 541 (2003) 57-63
32. Nicoletti I., Megliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring thymocytes apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139 (1991) 271-279
33. Ormerod M.C. Flow cytometry in the study of apoptosis. In: Ormerod M.C. (Ed). Flow Cytometry-A Practical Approach (2000), Oxford University Press, Oxford 235-247
34. Bueno da Silva A.E.B., Brumatti G., Russo F.O., Green D.R., and Amarante-Mendes G.P. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death Differ. 10 (2003) 592-598
35. Simões-Wüst A.P., Schürpf T., Hall J., Stahel R.A., and Zangemeister-Wittke U. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res. Treat. 76 (2002) 157-166
36. Ho H.K., Hu Z.-H., Tzung S.-P., Hockembery D.M., Fausto N., Nelson S.D., et al. BCL-xL overexpression effectively protects against tetrafluoroethylcysteine-induced intramitochondrial damage and cell death. Biochem. Pharmacol. 69 (2005) 147-157
37. Antonsson B., and Martinou J.C. The Bcl-2 protein family. Exp. Cell Res. 256 (2000) 50-57
38. Chanan-Khan A.A. Bcl-2 antisense therapy in multiple myeloma. Oncology 13 (2004) 21-24
39. Hara T., Omura-Minamisawa M., Chao C., Nakagami Y., Ito M., and Inoue T. Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 61 (2005) 517-528